XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Dec. 16, 2022
Jul. 31, 2022
May 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Risk-free interest rates       3.76% 2.24%  
Expected life (in years)       6 years 3 months 6 years 3 days  
Expected Volatility       105.99% 106.98%  
Dividend yield       0.00% 0.00%  
Share based payment award description   the achievement of performance minimum, target, and maximum goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal year 2022 the Company of average market capitalization minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning on January 1, 2022 and ending on December 31, 2024      
Increase in fair value       $ 58,500    
Vita Graft [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Vested percentage   50.00% 50.00%      
Determal O [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Vested percentage   50.00% 50.00%      
Determa CNI [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share based payment award vesting rights description The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December 16, 2022          
Performance Shares [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Share based payment award description           50
Performance Shares [Member] | Executive Officers and Employees [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares   23,750 61,875      
Market Based Awards [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Risk-free interest rates       2.72%    
Expected life (in years)       2 years 7 months 6 days    
Expected Volatility       95.00%    
Market Based Awards [Member] | Executive Officers and Employees [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares     12,500      
Monte Carlo Valuation Technique [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Risk-free interest rates       2.00%    
Expected life (in years)       2 years 9 months 18 days    
Expected Volatility       100.00%    
Dividend yield       0.00%    
2010 Stock Option Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock, shares authorized       260,000    
Performance-Based Options [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Grant date fair value       $ 117,625    
2018 Incentive Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]            
Common stock, shares authorized       1,050,000